Email
Print
Pulmonary Arterial Hypertension (PAH) Market - Forecast(2024 - 2030)
Pulmonary Arterial Hypertension (PAH) Market Overview
The Pulmonary Arterial Hypertension (PAH) Market Size is estimated
to reach $9.7 billion by 2027 and is poised to grow at a CAGR of 5.6% over the
forecast period of 2022-2027. Pulmonary
arterial hypertension is a rare and progressive condition, elevated by blood
pressure in the pulmonary arteries, which deliver blood from the heart to the
lungs. When pulmonary arteries develop a smaller diameter or are obstructed,
PAH occurs, owing to rising risk factors such as HIV, sedentary lifestyle,
cigarette and alcohol use, smoking and other idiopathic illnesses. Shortness
of breath, chest pain, fatigue, passing out and swelling in the ankles and
legs are primary symptoms of PAH. PAH is most common in women between the ages
of 30-60. Approximately 15-20% of patients with PAH have heritable PAH
according to Who in the year 2021. BMPR2 gene alterations (mutations) are the
most frequent genetic cause of heritable PAH, while other genes and pathways
have recently been discovered.
Pulmonary Arterial Hypertension (PAH), is a rare disease and no
actual reason is known for what caused the disease. Preventive medication is
discovered to minimise the effect of pulmonary arterial hypertension. Drugs
such as endothelin receptor antagonists (ERAs), phosphodiesterase inhibitors
(PDE5 inhibitors), prostacyclin and prostacyclin analogs, SGC stimulators, endothelin
& endothelin receptor antagonists, guanylate cyclase and others are
helpful to minimise the Pulmonary Arterial Hypertension. Also, the major key
market players launched new drugs and expand their product portfolio with
innovative research & developments and joint venture helps to grow the
Pulmonary Arterial Hypertension (PAH) Industry over the forecast period
2022-2027.
Pulmonary Arterial Hypertension (PAH) Market Report Coverage
The report: “Pulmonary Arterial Hypertension (PAH) Market Forecast
(2022-2027)", by Industry ARC covers an in-depth analysis of the following
segments in the Pulmonary Arterial Hypertension (PAH) Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to advanced health infrastructure and the presence of key market players assisting the growth of Pulmonary Arterial Hypertension (PAH) Market Size in this region.
- The Pulmonary Arterial Hypertension (PAH) Market is predicted to increase owing to innovative drugs launched by key market players and research and development.
- However, the lack of skilled professionals and the high rate of mortality may limit market growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Pulmonary Arterial Hypertension (PAH) Market Report.
Pulmonary Arterial Hypertension (PAH) Market: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Pulmonary Arterial Hypertension (PAH) Market Segment Analysis - by Drug Class
The Pulmonary Arterial Hypertension (PAH) Market based on drug class
can be further segmented into Endothelin Receptor Antagonists (ERAs), PDE-5
Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators and Others.
The Prostacyclin and Prostacyclin Analogs segment held a dominant market share in
the year 2021. Patients with pulmonary arterial hypertension have lower amounts
of the powerful vasodilator prostacyclin, which causes the pulmonary vascular
to constrict. Hence, a synthetic version of prostacyclin, a naturally occurring
chemical created by the body, is known as PAH prostacyclin analogs and is
used in three forms to treat pulmonary arterial hypertension that are epoprostenol,
iloprost and treprostinil (PAH). Owing to such attributes Prostacyclin and
Prostacyclin Analogs segment fuel the growth of the Pulmonary Arterial Hypertension
(PAH) Market Share.
However, SGC Stimulators are
estimated to grow with the fastest CAGR of 6.1%
over the forecast period 2022-2027. This is owing to the use of SGC
Stimulators by raising nitric oxide levels in the heart and blood vessels,
oxidative stress can be reduced. Low levels of cyclic guanosine monophosphate
are present in one-fourth of people with heart failure (cGMP). The use of
soluble Guanylate Cyclase stimulators (sGCS) can help to delay the need for
hospitalization for severe heart failure by reducing the stiffness of cardiac
cells and blood vessels by increasing the production of cGMP. Owing such
emergency use of SGC stimulators for PAH fuels the growth of the Pulmonary
Arterial Hypertension (PAH) Market Share over the forecast period 2022-2027.
Pulmonary Arterial Hypertension (PAH) Market Segment Analysis - by Type
The pulmonary Arterial Hypertension (PAH) Market based on the type can
be further segmented into Branded and Generic. The Branded segment held a dominant market
share in the year 2021. This is owing to an increase in research and
developments and the launch of new innovative drugs to treat PAH. For instance,
in May 2022, FDA approved Tyvaso DPI (treprostinil) inhalation powder for the
treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary
hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to
improve exercise ability. Owing to such innovative product launches by key
market players grow the segment and drive the growth of the Pulmonary Arterial
Hypertension (PAH) Market Share.
However, the Generic segment is estimated
to grow with the fastest CAGR of 5.9% over the forecast period
2022-2027. This is owing to the expiry of key patents for drugs which is
useful for the treatment of PAH. Also, the growing demand for a generic drug to
reduce the cost of healthcare expenditure help to grow the segment. For
Instance, in April 2021, Zydus Healthcare Limited received FDA clearance to
commercialize a generic version of Opsumit Macitentan Tablets. Such increasing
use of generic drugs aids the growth of the Pulmonary Arterial Hypertension (PAH)
Market Share over the forecast period 2022-2027.
Pulmonary Arterial Hypertension (PAH) Market Segment Analysis - by Geography
The Pulmonary Arterial Hypertension (PAH) Market based on
Geography can be further segmented into North America, Europe, Asia-Pacific,
South America and the Rest of the World. North America held a dominant market
share of 37% in the year 2021. This is owing to the increasing prevalence of
PAH in this region. According to American Lung Association, about 500–1000 new instances of PAH are detected in the United States each year, making it a rare illness, and about 15 to 20% of PAH patients have inherited the illness. Also
increasing consumption of tobacco leads to severe lung disease and may cause pulmonary
arterial hypertension (PAH). According to the Center for Disease Control and
Prevention (CDC), Tobacco use is the leading cause of preventable disease,
disability and death in the United States. Nearly 40 million U.S., adults
still smoke cigarettes. Such increasing consumption of tobacco products in this
region is a preventable cause of pulmonary arterial hypertension (PAH). Such
factors help to drive the growth of Pulmonary Arterial Hypertension (PAH)
Market Size in this region.
However, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2022. This is owing to the increasing prevalence of Chronic Obstructive Pulmonary Disease (COPD) in this region. COPD is one of the leading causes of morbidity, disability and mortality in this region as most cases are recorded in low-income and middle-income countries. According to the research paper published in May 2022 in The Lancet Respiratory Medicine, low-income and middle-income countries account for more than three-quarters of global COPD cases. Additionally, Cardiovascular Disease that is linked with tobacco consumption and pulmonary arterial hypertension is high in low-income and middle-income countries. According to World Health Organisation (WHO), 75% of CVD occur in low-income and middle-income countries. Such factors help to fuel the Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size over the forecast period 2022-2027.
Pulmonary Arterial Hypertension (PAH) Market Drivers
Growing Women Population Between 30 to 60 Age Group Helps to Drive Market.
The increasing population and the growing number of chronic diseases around the world help to drive the market. Pulmonary Arterial Hypertension (PAH) mostly occurs in women aged 30 to 60. Further, according to the World Bank, females between the ages of 15 to 64 held 65% sharethe total female population in 2020. Also, an increasing number of other chronic diseases in females, such as stroke, cholesterol and stress may lead to (PAH). Stroke is the fifth leading cause of death in females and their main reason is hypertension. According to the Center for Disease Control and Prevention (CDC), More than 1 in 3 Hispanic women have blood pressure above 130/90 mm Hg. Such factors contribute to the hike in the growth Pulmonary Arterial Hypertension (PAH) Industry over the forecast period 2022-2027.
Increasing Awareness About Pulmonary Arterial Hypertension (PAH) Aid Market Growth.
For effective treatment, prevention, early identification and personalized therapy, awareness is very important. People are more inclined to take preventative action and go for screenings, testing and check-up if they are aware of diseases and their symptoms. A significant obstacle to optimal health is a lack of knowledge about disorders or choices for screening and treatment. According to Health System Tracker, Health spending per person in the U.S., was $11,945 in 2020, which was over $4,000 more expensive than any other high-income nation. The average amount spent on health per person in comparable countries ($5,736) is roughly half that of the U.S. Such increasing awareness about chronic disease and an increase in health care spending reduce cases of chronic diseases like HIV, according to HIV.gov, new HIV infection in the U.S is declined by 8% from 37,800 in 2015 to 34,800 in 2020. Such an increase in per capita health care expenditure owing to increasing awareness helps to grow the Pulmonary Arterial Hypertension (PAH) Industry over the forecast period 2022-2027.
Pulmonary Arterial Hypertension (PAH) Market Challenges
Lack of Skilled Professionals is Hampering the Market Growth.
The chain of hospitals, clinical laboratories and diagnostic
centers spreads all over the globe. With the increasing global population,
there is an increased load on the healthcare system to provide efficient
service. Some factors are hindering the growth of healthcare sector such as high
investment on infrastructure, equipment’s and machinery, lack of skilled
professional, etc. According to the WHO, the number
of healthcare workers around the globe would reduce by 12.9 million by 2035.
The global shortage of healthcare personnel is linked to several factors
including an aging workforce, a decline in the number of persons joining the
profession, early retirements, insufficient training and increased demands
from a growing and aging population, which hamper market growth over the
forecast period 2022-2027.
Pulmonary Arterial Hypertension (PAH) Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Pulmonary
Arterial Hypertension (PAH) Market. The top 10 companies in the Pulmonary
Arterial Hypertension (PAH) Market are:
- United
Therapeutics Corporation
- Bayer AG
- Gilead
Sciences Inc.
- Johnson
& Johnson
- Viatris
Inc.
- GlaxoSmithKline
- Sandoz
Inc. (Novartis)
- Lupin
Pharmaceuticals Inc.
- Sun
Pharmaceutical Industries Inc.
- Teva
Pharmaceutical Industries Ltd.
Recent Developments
- In March 2022, Gilead Sciences and Merck announced an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV.
- In January 2022, Lupin pharmaceutical partnered with Shenzhen Foncoo Pharmaceuticals to introduce products in China. This collaboration agreement - the business's first in China - reinforces its dedication to providing world high-quality generic and sophisticated generic medications to patients all around the world.
- In April 2021, United Therapeutics Corporation announced FDA approval and launch of Tyvaso Inhalation Solution for the treatment of patients with Pulmonary Hypertension Associated with Interstitial Lung Disease. The FDA approval of the supplemental New Drug Application (sNDA) for Tyvaso for PH-ILD is supported by data from INCREASE, the largest and most comprehensive completed study of adult patients with PH-ILD.
Relevant Titles
Report Code: HCR 75469
Report Code: HCR 0369
Report Code: HCR 0344